BIODESIX, INC. Selling and Marketing Expense
BIODESIX, INC. (BDSX) reported Selling and Marketing Expense of $2.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-05
- BIODESIX, INC. selling and marketing expense for the quarter ending 2026-06-30 was $2.23M, a 12.71% increase year-over-year.
- BIODESIX, INC. selling and marketing expense for the quarter ending 2026-03-31 was $2.21M, a 18.30% increase year-over-year.
- BIODESIX, INC. selling and marketing expense for the quarter ending 2025-12-31 was $1.96M, a 29.27% increase year-over-year.
- BIODESIX, INC. selling and marketing expense for the quarter ending 2025-09-30 was $1.75M, a 7.97% increase year-over-year.
- BIODESIX, INC. selling and marketing expense for fiscal 2025 was $7.56M, a 0.16% decline from fiscal 2024.
- BIODESIX, INC. selling and marketing expense for fiscal 2024 was $7.57M, a 5.27% increase from fiscal 2023.
- BIODESIX, INC. selling and marketing expense for fiscal 2023 was $7.20M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.23M 10-Q · filed 2026-08-05 | $4.45M 10-Q · filed 2026-08-05 | $6.41M derived: sum of 3 quarters · filed 2026-08-05 | $8.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.21M 10-Q · filed 2026-05-04 | $4.17M derived: sum of 2 quarters · filed 2026-05-04 | $5.92M derived: sum of 3 quarters · filed 2026-05-04 | $7.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.71M derived: sum of 2 quarters · filed 2026-02-26 | $5.69M derived: sum of 3 quarters · filed 2026-08-05 | $7.56M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.75M 10-Q · filed 2025-11-03 | $3.73M derived: sum of 2 quarters · filed 2026-08-05 | $5.60M 10-Q · filed 2025-11-03 | $7.12M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.98M 10-Q · filed 2026-08-05 | $3.85M 10-Q · filed 2026-08-05 | $5.37M derived: sum of 3 quarters · filed 2026-08-05 | $6.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.87M 10-Q · filed 2026-05-04 | $3.39M derived: sum of 2 quarters · filed 2026-05-04 | $5.00M derived: sum of 3 quarters · filed 2026-05-04 | $7.30M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.14M derived: sum of 2 quarters · filed 2026-02-26 | $5.43M derived: sum of 3 quarters · filed 2026-02-26 | $7.57M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.62M 10-Q · filed 2025-11-03 | $3.91M derived: sum of 2 quarters · filed 2025-11-03 | $6.06M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $2.29M 10-Q · filed 2025-08-07 | $4.44M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $2.15M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $7.20M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |